Related Experiment Videos
Rationale and risks of novel immunomodulatory therapies in rheumatoid arthritis
1Arthritis Center, Presbyterian Hospital of Dallas and The University of Texas Southwestern Medical School at Dallas, Dallas, Texas 75231, USA.
Abstract:
The need for new therapies for the treatment of rheumatoid arthritis (RA) has arisen during an era where clinicians have realized that RA is a far more ominous condition than was thought previously. The last decade has revealed numerous studies depicting the limited long-term efficacy and tolerability of conventional disease-modifying antirheumatic drug (DMARD) therapies. Moreover, DMARDs have not been shown to be truly capable of modifying articular, functional and radiographic outcomes in patients with RA. These issues have been raised amidst significant advances in our understanding of the immunopathogenesis of RA and advances in biotechnology. Such advances have led to a revised approach to using conventional DMARDs, while new pharmacologic and biospecific interventions are being developed. This chapter will discuss the clinical and biologic rationale for novel therapies for patients with RA and the hazards imposed by the therapeutic manipulation of various immune effector mechanisms in patients with RA.
Insights
Conventional rheumatoid arthritis (RA) treatments show limited efficacy. New biologic therapies are being developed to address RA
Area of Science:
- Immunology and Rheumatology
- Biotechnology and Drug Development
Background:
- Rheumatoid arthritis (RA) is increasingly recognized as a severe condition with significant long-term impacts.
- Conventional disease-modifying antirheumatic drug (DMARD) therapies demonstrate limited long-term efficacy and tolerability.
- DMARDs have not proven effective in modifying articular, functional, or radiographic outcomes in RA patients.
Purpose of the Study:
- To explore the clinical and biologic rationale for novel therapeutic strategies in rheumatoid arthritis.
- To discuss the potential risks associated with manipulating immune effector mechanisms for RA treatment.
Main Methods:
- Review of recent studies on DMARD efficacy and tolerability.
- Analysis of advances in understanding RA immunopathogenesis.
- Examination of progress in biotechnology for therapeutic development.
Main Results:
- Conventional DMARDs have shown insufficient long-term effectiveness and tolerability.
- Significant advancements in understanding RA's immune basis and biotechnology are paving the way for new treatments.
- A revised approach to conventional DMARD use is emerging alongside new interventions.
Conclusions:
- There is a critical need for novel therapies for rheumatoid arthritis due to the limitations of current treatments.
- Advances in immunology and biotechnology support the development of new pharmacologic and biospecific interventions for RA.
- Careful consideration of the hazards of immune system manipulation is essential when developing new RA therapies.